Tag: Drugs
Search News
Immunotherapy for advanced bladder cancer
18th September 2020
An immunotherapy drug called ‘avelumab’ has been shown to significantly improve survival in patients with the most common type of bladder cancer, according to results from a phase III clinical trial led by Professor Tom Powles.
Read more
Investigating new treatment options for mesothelioma
16th September 2020
Results from a phase I clinical trial led by Professor Peter Szlosarek were recently published in JTO Clinical and Research Reports. The trial was investigating the safety and efficacy of a new drug combination for the treatment of mesothelioma. We spoke to Professor Szlosarek to find out more about the trial, and how the drug combination may be able to help patients with mesothelioma.
Read more
Immunotherapy for advanced bladder cancer
29th May 2020
An immunotherapy drug called ‘avelumab’ has been shown to significantly improve survival in patients with the most common type of bladder cancer, according to results from a phase III clinical trial led by Professor Tom Powles.
Read more
Immune therapy reduces risk of recurrence in aggressive breast cancer
27th February 2020
An immune therapy for the most aggressive form of breast cancer can substantially reduce the risk of the disease returning, according to a clinical trial led by Professor Peter Schmid of Barts Cancer Institute, Queen Mary University of London.
Read more
Tackling resistance in skin cancer
13th January 2020
Researchers have found that melanoma cells fight anti-cancer drugs by changing their internal skeleton (cytoskeleton) – opening up a new therapeutic route for combating skin and other cancers that develop resistance to treatment.
Read more
IBIS-II – new results from international breast cancer study
12th December 2019
The Queen Mary University of London professor leading an international breast cancer study says anastrozole – rather than tamoxifen – should be the preventive drug-of-choice for post-menopausal women at increased risk of developing the disease.
Read more